共 50 条
- [1] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative, hormone receptor-positive breast cancer and bone metastasesCANCER RESEARCH, 2017, 77Rugo, H. S.Drumea, K. C.Campone, M.Barnadas, A.Petrenciuc, O.Zhang, A.Li, R.Coleman, R. E.
- [2] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastasesANNALS OF ONCOLOGY, 2016, 27Rugo, H.Petrenciuc, O.Zhang, A.Li, R.Coleman, R. E.
- [3] A phase 2 randomized, double-blind, placebo-controlled trial of radium-223 dichloride with exemestane and everolimus in patients with HER2-negative hormone receptor-positive breast cancer and bone metastases.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Rugo, Hope S.Li, RuiPetrenciuc, OanaZhang, AmilyColeman, Robert E.
- [4] A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy ± radium-223 dichloride in human epidermal growth factor receptor 2-negative, hormone receptor-positive breast cancer patients with bone metastasesCANCER RESEARCH, 2016, 76Coleman, R. E.Huang, L.Petrenciuc, O.Zaccarini, P.Rugo, H. S.
- [5] A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride in HER2-negative, hormone receptor-positive breast cancer patients with bone metastasesCANCER RESEARCH, 2017, 77Coleman, R. E.Fried, G.Petrenciuc, O.Sawhney, A.Li, R.Rugo, H. S.
- [6] A phase 2 randomized, double-blind, placebo-controlled trial of endocrine therapy ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients with bone metastases.JOURNAL OF CLINICAL ONCOLOGY, 2016, 34 (15)Coleman, Robert E.Li, RuiSawhney, Amrita G.Petrenciuc, OanaRugo, Hope S.
- [7] A phase 2 randomized, double-blind, placebo-controlled trial of hormone therapy (HT) ± radium-223 dichloride (Ra-223) in HER2- hormone receptor+ breast cancer patients (pts) with bone metastases (mets).JOURNAL OF CLINICAL ONCOLOGY, 2015, 33 (15)Coleman, Robert E.Huang, LipingPetrenciuc, OanaZaccarini, Paola
- [8] Double-Blind, Placebo-Controlled, Multicenter, Randomized, Phase IIB Neoadjuvant Study of LetrozoleLapatinib in Postmenopausal Hormone Receptor-Positive, Human Epidermal Growth Factor Receptor 2-Negative, Operable Breast CancerJOURNAL OF CLINICAL ONCOLOGY, 2014, 32 (10) : 1050 - +Guarneri, ValentinaGenerali, Daniele GiulioFrassoldati, AntonioArtioli, FabrizioBoni, CorradoCavanna, LuigiTagliafico, EnricoMaiorana, AntoninoBottini, AlbertoCagossi, KatiaBisagni, GiancarloPiacentini, FedericoFicarra, GuidoBettelli, StefaniaRoncaglia, EnricaNuzzo, SimonaSwaby, RamonaEllis, CatherineHolford, ClareConte, PierFranco
- [9] Radium-223 (223Ra) in combination with exemestane and everolimus (EXE-EVE) in patients (pts) with hormone receptor-positive, human epidermal growth factor receptor 2-negative (HR+/HER2-) metastatic breast cancer (MBC) with bone metastases: A phase II studyANNALS OF ONCOLOGY, 2022, 33 : S211 - S212Rugo, H. S.Drumea, K.Lee, S. C.Campone, M.Van Poznak, C.Neven, P.Alonso, E. VegaNaume, B.Siegel, J. M.Li, R.Uema, D.Wagner, V. J.Coleman, R. E.
- [10] Radium-223 in women with hormone receptor-positive bone-metastatic breast cancer receiving endocrine therapy: pooled analysis of two international, phase 2, randomized, double-blind, placebo-controlled trialsBreast Cancer Research and Treatment, 2024, 204 : 249 - 259Hope S. RugoCatherine H. Van PoznakPatrick NevenIwona DanielewiczSoo Chin LeeMario CamponeJeannie Y. K. ChikEstela Vega AlonsoBjørn NaumeEtienne BrainJonathan M. SiegelRui LiDeise UemaVolker J. WagnerRobert E. Coleman